Multiple guidelines recommend treating post-traumatic stress disorder(PTSD) with psychotherapy first line. However, such approaches may not suffice for many patients, necessitating the use of pharmacological agents. Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants are often used in the first line. Given the multiple symptom domains that affect PTSD patients, combination therapy with anxiolytics and benzodiazepines, as well as mood stabilizers, is widely used. Atypical antipsychotics may also be prescribed to patients who do not respond to prior lines of therapy. Given patients’ variable response rates and comorbid symptoms, treatment of PTSD follows a fragmented and individualized approach. In this report, we use national patient-level claims data to explore the use of key therapies for PTSD in both newly diagnosed and recently treated patients.

Questions answered

  • What percentage of diagnosed patients receive pharmacologic treatments for the condition, and what is the average length of time between diagnosis and drug therapy?
  • Which agents garner the highest patient share among therapies used in PTSD patients? Which first line agents do newly diagnosed patients most commonly receive? What proportion progress to second and to third lines of therapy? Of these patients, what percentage receive multiple therapies?
  • In general, how compliant and how persistent are PTSD patients with pharmacotherapy?

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key companies: Allergan, Janssen, Lundbeck, Otsuka, Sunovion, Takeda

Key drugs: Latuda, Viibryd, Vraylar, Rexulti, Fetzima, Trintellix, aripiprazole, bupropion, escitalopram, anxiolytics/benzodiazepines, antiepileptic drugs, sertraline

Key analysis provided:

  • Brand use across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Table of contents

  • Post Traumatic Stress Disorder - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

Author(s): Andrea Witt, PhD

Andrea S. Witt, Ph.D., is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Decision Resources Group where she oversees a team of 14 Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.

 Dr. Witt has been with Decision Resources Group for over 12 years, following CNS markets and trends. Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.